FDA Approves ANI Generic Everolimus Tablets
Analysis based on 7 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026
The approval is a modest positive for ANI Pharmaceuticals, adding a limited-competition generic with roughly $123 million in annual U.S. sales to its portfolio and supporting its multi-product launch target. The impact on Novartis is marginal, as generic entry on a small Afinitor Disperz franchise poses limited revenue risk to the broader company.
ANI Pharmaceuticals received final approval from the U.S. United States — Food and Drug Administration for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2mg, 3mg and 5mg strengths. The product is the generic version of Novartis' Afinitor Disperz, which is approved for certain conditions associated with tuberous sclerosis complex. According to IQVIA moving annual total data for July 2026 cited by the company, U.S. annual sales for Everolimus Tablets for Oral Suspension were approximately $123 million. ANI CEO Nikhil Lalwani said the approval reflects continued execution on technically demanding formulations and that the company remains on track to launch at least 15 new generic products in 2026. The approval expands ANI's U.S.-focused generics portfolio and adds to its commercial product lineup. ANIP shares closed at $77.91 on Tuesday, down 1.19%, and traded at $78.99 in pre-market trading following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard